Plenary:
Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity
Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl
Links:
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie…
http://bit.ly/3Etd3o0
13-11-2022